{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:54:45Z","timestamp":1792065285491,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,4,20]],"date-time":"2013-04-20T00:00:00Z","timestamp":1366416000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40261-013-0082-0","type":"journal-article","created":{"date-parts":[[2013,4,19]],"date-time":"2013-04-19T11:10:25Z","timestamp":1366369825000},"page":"419-427","source":"Crossref","is-referenced-by-count":79,"title":["Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study"],"prefix":"10.1007","volume":"33","author":[{"given":"Heino","family":"Stass","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Nagelschmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Willmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Delesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybille","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,20]]},"reference":[{"issue":"3","key":"82_CR1","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/thx.2005.041822","volume":"61","author":"E Sapey","year":"2006","unstructured":"Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006;61(3):250\u20138.","journal-title":"Thorax"},{"issue":"8","key":"82_CR2","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.rmed.2007.03.009","volume":"101","author":"PT King","year":"2007","unstructured":"King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med. 2007;101(8):1633\u20138.","journal-title":"Respir Med"},{"key":"82_CR3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/clinids\/21.4.839","volume":"21","author":"RB Moss","year":"1995","unstructured":"Moss RB. Cystic fibrosis: pathogenesis, pulmonary infection, and treatment. Clin Infect Dis. 1995;21:839\u201351.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"82_CR4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.diagmicrobio.2010.04.008","volume":"68","author":"AD Valderrey","year":"2010","unstructured":"Valderrey AD, Pozuelo MJ, Jimenez PA, et al. Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. Diagn Microbiol Infect Dis. 2010;68(1):20\u20137.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"82_CR5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/ppul.1950120306","volume":"12","author":"RL Henry","year":"1992","unstructured":"Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992;12(3):158\u201361.","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"82_CR6","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1183\/09031936.97.10081754","volume":"10","author":"CB Wilson","year":"1997","unstructured":"Wilson CB, Jones PW, O\u2019Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J. 1997;10(8):1754\u201360.","journal-title":"Eur Respir J"},{"issue":"6","key":"82_CR7","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1067\/mpd.2003.197","volume":"142","author":"M Kulich","year":"2003","unstructured":"Kulich M, Rosenfeld M, Goss CH, et al. Improved survival among young patients with cystic fibrosis. J Pediatr. 2003;142(6):631\u20136.","journal-title":"J Pediatr"},{"issue":"1","key":"82_CR8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","volume":"340","author":"BW Ramsey","year":"1999","unstructured":"Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340(1):23\u201330.","journal-title":"N Engl J Med"},{"issue":"4","key":"82_CR9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.201005-0756OC","volume":"183","author":"MP Murray","year":"2011","unstructured":"Murray MP, Govan JR, Doherty CJ, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011;183(4):491\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"82_CR10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1753465807082692","volume":"1","author":"M Miravitlles","year":"2007","unstructured":"Miravitlles M. Do we need new antibiotics for treating exacerbations of COPD? Ther Adv Respir Dis. 2007;1(1):61\u201376.","journal-title":"Ther Adv Respir Dis"},{"issue":"10","key":"82_CR11","first-page":"1313","volume":"50","author":"DE Geller","year":"2005","unstructured":"Geller DE. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care. 2005;50(10):1313\u201321.","journal-title":"Respir Care"},{"issue":"3","key":"82_CR12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/jac\/48.3.391","volume":"48","author":"O Ciofu","year":"2001","unstructured":"Ciofu O, Fussing V, Bagge N, et al. Characterization of paired mucoid\/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. J Antimicrob Chemother. 2001;48(3):391\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"82_CR13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.121.1.55","volume":"121","author":"RB Moss","year":"2002","unstructured":"Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest. 2002;121(1):55\u201363.","journal-title":"Chest"},{"key":"82_CR14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1465-9921-11-10","volume":"11","author":"S Sethi","year":"2010","unstructured":"Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10.","journal-title":"Respir Res"},{"issue":"11","key":"82_CR15","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1128\/AAC.42.11.2956","volume":"42","author":"LJ Piddock","year":"1998","unstructured":"Piddock LJ, Johnson M, Ricci V, et al. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob Agents Chemother. 1998;42(11):2956\u201360.","journal-title":"Antimicrob Agents Chemother"},{"key":"82_CR16","volume-title":"Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis","author":"J Alder","year":"2011","unstructured":"Alder J, Wilson R, Welte T, et al. Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis. Amsterdam: European Respiratory Society; 2011."},{"key":"82_CR17","unstructured":"Endermann R, Labischinski H, Ladel C, et al. Treatment of bacterial diseases of the respiratory organs. US Patent 2004\/0254194 A1. 2004."},{"issue":"2","key":"82_CR18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1023\/A:1007513213292","volume":"17","author":"LA Dellamary","year":"2000","unstructured":"Dellamary LA, Tarara TE, Smith DJ, et al. Hollow porous particles in metered dose inhalers. Pharm Res. 2000;17(2):168\u201374.","journal-title":"Pharm Res"},{"issue":"1","key":"82_CR19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1378\/chest.124.1.360","volume":"124","author":"MT Newhouse","year":"2003","unstructured":"Newhouse MT, Hirst PH, Duddu SP, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest. 2003;124(1):360\u20136.","journal-title":"Chest"},{"issue":"4","key":"82_CR20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","volume":"24","author":"DE Geller","year":"2011","unstructured":"Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J Aerosol Med Pulm Drug Deliv. 2011;24(4):175\u201382.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"82_CR21","unstructured":"Pharmacopoeia Online. 601 Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers (online). http:\/\/www.uspbpep.com\/usp31\/v31261\/usp31nf26s1_c601.asp . Accessed 16 Sept 2011."},{"key":"82_CR22","unstructured":"European Pharmacopoeia 6.2. https:\/\/www.pheur.org\/store\/images\/majbdd\/200710301703120.6-2%20E%20Index.pdf . Accessed 16 Sept 2011."},{"key":"82_CR23","unstructured":"Gupta A, Tarara T, Miller D, et al. A novel high-payload dry powder formulation of ciprofloxacin for management of chronic lung infections (abstract no. R6156). American Association of Pharmaceutical Scientists Annual Meeting, Washington; 23\u201327 Oct 2011."},{"issue":"4","key":"82_CR24","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1089\/jam.2006.19.456","volume":"19","author":"HA Tiddens","year":"2006","unstructured":"Tiddens HA, Geller DE, Challoner P, et al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of 6\u00a0years and older. J Aerosol Med. 2006;19(4):456\u201365.","journal-title":"J Aerosol Med"},{"issue":"3","key":"82_CR25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-007-9053-5","volume":"34","author":"S Willmann","year":"2007","unstructured":"Willmann S, Hohn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34(3):401\u201331.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"82_CR26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1478-5382(03)02342-4","volume":"1","author":"S Willmann","year":"2003","unstructured":"Willmann S, Lipworth BJ, Sevestre M, et al. PK-Sim: a physiologically based pharmacokinetic \u2018whole-body\u2019 model. Biosilico. 2003;1(4):121\u20134.","journal-title":"Biosilico"},{"key":"82_CR27","author":"R Wilson","year":"2012","unstructured":"Wilson R, Welte T, Polverino E, et al. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2012. doi: 10.1183\/09031936.00071312 .","journal-title":"Eur Respir J"},{"issue":"5","key":"82_CR28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1128\/AAC.26.5.741","volume":"26","author":"MA Gonzalez","year":"1984","unstructured":"Gonzalez MA, Uribe F, Moisen SD, et al. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother. 1984;26(5):741\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"82_CR29","unstructured":"Stass H, Baumann-Noss S, Delesen H, et al. Pharmacokinetics of inhaled ciprofloxacin powder (abstract no. P103). In: Proceedings of 31st European Cystic Fibrosis Conference, Prague; 11\u201314 June 2008."},{"issue":"4","key":"82_CR30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/AAC.30.4.614","volume":"30","author":"MJ Smith","year":"1986","unstructured":"Smith MJ, White LO, Bowyer H, et al. Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob Agents Chemother. 1986;30(4):614\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"82_CR31","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1128\/AAC.31.6.956","volume":"31","author":"KI Plaisance","year":"1987","unstructured":"Plaisance KI, Drusano GL, Forrest A, et al. Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1987;31(6):956\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"82_CR32","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1128\/AAC.30.3.444","volume":"30","author":"GL Drusano","year":"1986","unstructured":"Drusano GL, Standiford HC, Plaisance K, et al. Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1986;30(3):444\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"82_CR33","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1128\/AAC.32.10.1537","volume":"32","author":"A Forrest","year":"1988","unstructured":"Forrest A, Weir M, Plaisance KI, et al. Relationships between renal function and disposition of oral ciprofloxacin. Antimicrob Agents Chemother. 1988;32(10):1537\u201340.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"82_CR34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF01977494","volume":"3","author":"W Wingender","year":"1984","unstructured":"Wingender W, Graefe KH, Gau W, et al. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol. 1984;3(4):355\u20139.","journal-title":"Eur J Clin Microbiol"},{"issue":"6","key":"82_CR35","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1365-2125.2006.02835.x","volume":"63","author":"E Bondesson","year":"2007","unstructured":"Bondesson E, Bengtsson T, Nilsson LE, et al. Site of deposition and absorption of an inhaled hydrophilic solute. Br J Clin Pharmacol. 2007;63(6):722\u201331.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"82_CR36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ppul.20594","volume":"42","author":"DE Geller","year":"2007","unstructured":"Geller DE, Konstan MW, Smith J, et al. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007;42(4):307\u201313.","journal-title":"Pediatr Pulmonol"},{"issue":"1\u20132","key":"82_CR37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijpharm.2006.11.021","volume":"335","author":"EM Westerman","year":"2007","unstructured":"Westerman EM, de Boer AH, Le Brun PP, et al. Dry powder inhalation of colistin sulphomethate in healthy volunteers: a pilot study. Int J Pharm. 2007;335(1\u20132):41\u20135.","journal-title":"Int J Pharm"},{"issue":"4","key":"82_CR38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2006.10.010","volume":"6","author":"EM Westerman","year":"2007","unstructured":"Westerman EM, de Boer AH, Le Brun PP, et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros. 2007;6(4):284\u201392.","journal-title":"J Cyst Fibros"},{"issue":"5 Pt 1","key":"82_CR39","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1164\/ajrccm.160.5.9810080","volume":"160","author":"NR Crowther Labiris","year":"1999","unstructured":"Crowther Labiris NR, Holbrook AM, Chrystyn H, et al. Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1711\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"82_CR40","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/thx.45.12.939","volume":"45","author":"JM Goldman","year":"1990","unstructured":"Goldman JM, Bayston SM, O\u2019Connor S, et al. Inhaled micronised gentamicin powder: a new delivery system. Thorax. 1990;45(12):939\u201340.","journal-title":"Thorax"},{"issue":"1","key":"82_CR41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0939-6411(02)00044-9","volume":"54","author":"PP Brun Le","year":"2002","unstructured":"Le Brun PP, de Boer AH, Mannes GP, et al. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur J Pharm Biopharm. 2002;54(1):25\u201332.","journal-title":"Eur J Pharm Biopharm"},{"key":"82_CR42","unstructured":"EUCAST. European Committee on Antimicrobial Susceptibility Testing. MIC distribution (online). http:\/\/www.eucast.org . Accessed 1 Jan 2011."},{"key":"82_CR43","unstructured":"Weers J, Clark A, Challoner P. High dose inhaled powder delivery: challenges and techniques. In: Respiratory Drug Delivery IX: River Grove: Amy Davis Biggs 2004; pp 281\u20138."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-013-0082-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0082-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0082-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T21:11:07Z","timestamp":1562965867000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-013-0082-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,20]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["82"],"URL":"https:\/\/doi.org\/10.1007\/s40261-013-0082-0","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,20]]}}}